BROSSARD, Quebec, May 01, 2019 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce that it has signed a one-year agreement (the “Agreement”) with Organic Medical Growth OMG3 Inc. (“OMG”) which will enable DIAGNOS to have access to more than 7,800 points of sale across Colombia.
Under the Agreement, DIAGNOS’ AI diabetic retinopathy screening platform CARA will be available for trial in five pharmacies across Colombia. This will also serve as a starting point for the partnership between the two companies, both of which are committed to jointly work on future initiatives that target the use of CBD oil and other cannabis-based derivatives for diabetes.
“We are very pleased to join forces with OMG in order to make available our AI retinal solutions in Colombia so that thousands of patients can benefit from it. In the near future, we will explore the possibilities of combining DIAGNOS’ proprietary AI solutions for early detection of pathologies with cannabis-based medicinal products”, declared Mr. Andre Larente, President of DIAGNOS.
“We are excited about bringing DIAGNOS’ proprietary platform to Colombia through our partner’s distribution network. As a Canadian company with operations in Colombia, we welcome the opportunity to connect and facilitate relations between businesses in both countries, especially when they offer AI solutions that can directly impact and benefit people that suffer from specific health conditions. We further plan to explore other areas of collaboration with DIAGNOS, including opportunities to research and develop cannabis-based products that can be used by people suffering from diabetic retinopathy and other health issues linked to diabetes”, said Mr. Jorge Diaz, Founder & CEO of Organic Medical Growth OMG3 Inc.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information on DIAGNOS is available at www.diagnos.com and www.sedar.com.
About OMG
OMG is a Canadian corporation and investment holding company with a mission to grow and distribute high-quality organically sourced CBD oil for medicinal purposes with a direct to more than 7,800 points of sale in Colombia.
Additional information on OMG is available at www.organicmedicalgrowth.com
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.